Validation of 2 Syncope Risk Scores and Comparison With Physician Risk Estimation - Takeaways - MDSpire

Validation of 2 Syncope Risk Scores and Comparison With Physician Risk Estimation

  • By

  • Edward H. Suh

  • Carolyn Winskill

  • Dana L. Sacco

  • John DeAngelis

  • Daniel K. Nishijima

  • Jonathan Schimmel

  • Alan B. Storrow

  • Nancy E. Wood

  • Venkatesh Thiruganasambandamoorthy

  • Christopher W. Baugh

  • Robert E. Weiss

  • Marc A. Probst

  • May 19, 2026

  • 0 min

Share

  • 1

    Syncope and presyncope account for 2% to 3% of emergency department visits, with serious outcomes occurring in 5% to 10% of patients within 30 days.

  • 2

    The Canadian Syncope Risk Score (CSRS) and FAINT score are tools designed to stratify risk and guide clinical management for patients with syncope.

  • 3

    This study aimed to prospectively validate the CSRS and FAINT score in US emergency departments for patients aged 40 and older.

  • 4

    Participants were enrolled from six urban US emergency departments, targeting a sample size of 1232 patients to ensure adequate statistical power.

  • 5

    The study collected baseline clinical data and physician risk estimates to compare the performance of the CSRS and FAINT score against clinician judgment.

Original Source(s)

Validation of 2 Syncope Risk Scores and Comparison With Physician Risk Estimation

  • by Edward H. Suh, Carolyn Winskill, Dana L. Sacco, John DeAngelis, Daniel K. Nishijima, Jonathan Schimmel, Alan B. Storrow, Nancy E. Wood, Venkatesh Thiruganasambandamoorthy, Christopher W. Baugh, Robert E. Weiss, Marc A. Probst

  • May 19, 2026

Related Content

Case Report Highlights Heart Transplant for Complex Fontan Patient

This case demonstrates that even patients with highly complex congenital heart disease can safely undergo heart transplantation, offering a life-saving option when Fontan palliation is no longer sufficient.

  • by

  • April 9, 2026

  • 2 min
Forecasting Atrial Fibrillation Following Acute Coronary Syndrome: Findings from the BACS and BAMI Studies

Safety and efficacy of sacubitril/valsartan vs. benazepril administered as initial treatment for STEMI patients with mid-range ejection fraction: a propensity score matching analysis